Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 3Tumor-Agnostic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Hypoalphalipoproteinemias 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Rosuvastatin Calcium × Genitourinary × Clear all
NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Astellas Pharma Inc

Phase 1 Completed
24 enrolled
Genitourinary

Prostatic Neoplasms

NCT04776889 2021-03-02

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

National Cancer Institute, Egypt

Phase 4 Completed
70 enrolled
Genitourinary

Prostatic Neoplasms, Hypoalphalipoproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡